First Patient Enrolled in Gore TAG Thoracic Branch Endoprosthesis LSA Feasibility Study
Multi-Center Study to Assess Feasibility of Gore Device to Treat Historically Challenging Patient Population
GORE® VIABAHN® Endoprosthesis Found to Provide Superior Patency and Reduced Interventions Versus Balloon Angioplasty Alone for Challenging AV Access Cases
New data from Gore REVISE Clinical Study published online in Journal of Vascular Surgery illustrates role device can play in maintaining and salvaging failing dialysis circuits
First Patients Enrolled in the Gore RELINE MAX Clinical Study
108 patient trial to add evidence for treatment of in-stent restenosis using the GORE® VIABAHN® Endoprosthesis
Unique Biomaterial for Hernia Repair Receives FDA 510K Clearance
GORE® SYNECOR Biomaterial combines strength of PTFE with the tissue-building scaffold of GORE® BIO-A® Web to create an improved device for hernia repair
GORE® VIABAHN® Endoprosthesis Marks 20 Years of Proven Performance
Market-leading stent-graft has evolved to address range of indications, patient needs
FDA Approves First Balloon Expandable Stent Graft for Use in the Iliac Artery
GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Provides Improved Outcomes in Real-World Peripheral Arterial Disease Cases
Gore Prevails in Heart Device Patent Infringement Suit
W. L. Gore & Associates (Gore) today announced a favorable ruling involving the GORE® HELEX® Septal Occluder.
First Successful Implant of GORE® SYNECOR Biomaterial in a Ventral Hernia Patient
Unique biomaterial for hernia repair implanted for the first time in Gore’s Clinical Quality Improvement project
Global Vascular Thought Leaders Document Shift toward Individualizing Patient Care in Surgical Bypass
Presentations and Discussions from the Surgical Bypass Summit Available at www.surgicalbypass.com
Gore Announces Positive Results from REDUCE Clinical Study for PFO Closure
Study met its primary endpoint with PFO closure in conjunction with antiplatelet therapy, reducing recurrent stroke by > 75% over antiplatelet therapy alone